Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
PharmAla Biotech Holdings, Inc. ( (TSE:MDMA) ) just unveiled an announcement.
PharmAla Biotech Holdings has signed a binding supply agreement with Amsterdam University Medical Center in the Netherlands to provide LaNeo 40 mg MDMA capsules for a proposed clinical trial. The product will be repackaged into a new single-capsule format as part of the collaboration.
The agreement includes a three-year stability testing program for the single-capsule dosage, designed to generate data needed to develop commercial-grade blister packaging for LaNeo MDMA. This initiative strengthens PharmAla’s European clinical presence and supports its broader commercial strategy by paving the way for more standardized, efficient distribution to research and treatment sites worldwide.
PharmAla already maintains a European value chain to supply LaNeo MDMA for clinical research, and the Amsterdam UMC deal is subject to a separate quality agreement and regulatory approvals. The company continues to position itself as a key provider of clinical-grade MDMA and related molecules to researchers and commercial partners across multiple jurisdictions.
The most recent analyst rating on (TSE:MDMA) stock is a Hold with a C$0.10 price target. To see the full list of analyst forecasts on PharmAla Biotech Holdings, Inc. stock, see the TSE:MDMA Stock Forecast page.
Spark’s Take on TSE:MDMA Stock
According to Spark, TipRanks’ AI Analyst, TSE:MDMA is a Neutral.
The score is held back primarily by weak financial performance: deteriorating profitability, negative gross profit, and ongoing cash burn despite improving revenue. Technicals are mixed with only modest near-term strength, and valuation is constrained by losses (negative P/E) with no dividend support.
To see Spark’s full report on TSE:MDMA stock, click here.
More about PharmAla Biotech Holdings, Inc.
PharmAla Biotech Holdings Inc. is a biotechnology company focused on the research, development, and manufacturing of MDXX-class molecules, including MDMA. The company targets both alleviating the global shortage of clinical-grade MDMA for trials and select commercial uses, and advancing novel psychedelic-derived drug candidates while emphasizing regulatory compliance in its operations.
Average Trading Volume: 154,392
Technical Sentiment Signal: Sell
Current Market Cap: C$11.43M
See more data about MDMA stock on TipRanks’ Stock Analysis page.